Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Repaglinide effects on incretin response and oxidative stress in type 2 diabetes
2006-005331-25Phase 4Completed
- Sponsor
- Swansea Bay University Health Board
- Start
- Jan 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of repaglinide in type 2 diabetes mellitus (T2DM), sponsored by Swansea Bay University Health Board. Started Jan 2007; status: completed.
02
Drugs
repaglinide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2006-005331-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005331-25.